Combination aspirin and/or calcium chemoprevention with colonoscopy in colorectal cancer prevention: Cost-effectiveness analyses

Cancer Epidemiology Biomarkers and Prevention

Volumn 22, Issue 3, 2013, Pages 399-405

  Pence, Barbara C ^a   Belasco, Eric J ^c   Lyford, Conrad P ^b  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^c MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CALCIUM CARBONATE;

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER PREVENTION; CANCER SCREENING; CHEMOPROPHYLAXIS; CLINICAL EFFECTIVENESS; COLONOSCOPY; COLORECTAL ADENOMA; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MEDICARE; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROBABILITY; REIMBURSEMENT; REPEAT PROCEDURE; SENSITIVITY ANALYSIS; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADENOMA; ADULT; AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; CALCIUM; COHORT STUDIES; COLONOSCOPY; COLORECTAL NEOPLASMS; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DIETARY SUPPLEMENTS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MONTE CARLO METHOD; PROGNOSIS; RISK FACTORS; ROC CURVE; SURVIVAL RATE;

EID: 84876521342     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-12-0658     Document Type: Article

References (31)

1. Pence BC, Belasco EJ, Lyford CP. Prevention of colorectal cancer by aspirin and/or calcium: efficacy, mechanisms, and cost effectiveness. Curr Colorectal Cancer Rep. 2012 doi 10.1007/s11888-011-0115-0.
2. Chan AT, Arber N, Burn J, Chia WK, Elwood P, Hull MA, et al. Aspirin in the chemoprevention of colorectal neoplasia: an overview. Cancer Prev Res 2012;5:164-78.
3. Carroll C, Cooper K, Papioannou D, Hind D, Pilgrim H, Tappenden P. Supplemental calcium in the chemoprevention of colorectal cancer: a systematic review and meta-analysis. Clin Ther 2010; 32:789-803.
4. Winawer SJ, Zauber AG, Fletcher RH, Stillman JS, O'Brien MJ, Levin B. Guidelines for colonoscopy surveillance after polypectomy: a consensus update by the U.S. Multi-Society Task Force on colorectal cancer and the American Cancer Society. Gastroenterology 2006;130: 1872-85. (Pubitemid 43668826)
5. Dube C, Rostom A, Lewin G, Tsertsvadze A, Barrowman N, Code C, et al. The use of aspirin for primary prevention of colorectal cancer: a systematic review prepared for the U.S. Preventive Services Task Force. Ann Int Med 2007;146:365-75. (Pubitemid 351650597)
6. Din FV, Theodoratou E, Farrington SM, Tenesa A, Barnetson RA, Cetnarskyj R, et al. Effect of aspirin and NSAIDS on risk and survival from colorectal cancer. Gut 2010;59:1670-9.
7. Dupont AW, Arguedas MR, Wilcox CM. Aspirin chemoprevention in patients with increased risk for colorectal canxcer: a cost-effectiveness analysis. Aliment Pharmacol Ther 2007;26:431-41. (Pubitemid 47063144)
8. Shaukat A, Parekh M, Lipscomb J, Ladabaum U. Can calcium chemoprevention of adenomarecurrence substitute or serve as an adjunct for colonoscopic surveillance? Int J Technol Assess Health Care 2009;25:222-31.
9. Zauber AG, Winnawer SJ, O'Brien MJ, Lansdrop-Vogelaar I, van Ballegooijen M, Hankey BF, et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012;366:687-96.
10. Mitka M. Colorectal cancer screening rates still fall far short of recommended levels. JAMA 2008;299:622. (Pubitemid 351252741)
11. Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2012. CA Cancer J Clin 2012;62:129-42.
12. Quintero E, Castells A, Bujanda L, Cubiella J, Salas D, Lanas A, et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012;366:697-706.
13. Hassan C, Rex DK, Cooper GS, Zullo A, Launois R, Benamouuzig R. Primary prevention of colorectal cancer with low-dose aspirin in combination with endoscopy: a cost-effectiveness analysis. Gut 2012;61:1172-9.
14. Squires H, Tappenden P, Cooper K, Carroll C, Logan R, Hind D. Costeffectiveness of aspirin, celecoxib, and calcium chemoprevention for colorectal cancer. Clin Ther 2011;33:1289-305.
15. Baron JA, Cole BF, Sandler RS, Haile RW, Ahnen D, Bresalier R, et al. A randomized trial of aspirin to prevent colorectal cancer. N Engl J Med 2003;348:891-9. (Pubitemid 36297997)
16. Baron JA, Beach M, Mandel JS, van Stolk RU, Haile RW, Sandler RS, et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999;340:101-7. (Pubitemid 29054844)
17. Grau MV, Baron JA, Barry EL, Sandler RS, Haile RW, Mandel JS, et al. Interaction of calcium supplementation and nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2005;14:2353-8. (Pubitemid 41437836)
18. Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald R, et al. Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet 2009;10: 501-7.
19. Social Security Administration. Actuarial life table. Rochester, NY: Actuarial Publications; 2012 [cited 2012 Apr 30]. Available from: http://www.ssa.gov/oact/STATS/table4c6.html.
20. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Hayes RB, Church T, et al. Utilization of surveillance colonoscopy in community practice. Gastroenterology 2010;138:27-30.
21. Strul H, Kariv R, Leshno M, Halak A, Jakubowicz M, Santi M, et al. The prevalence rate and anatomic location of colorectal adenoma and cancer detected by colonoscopy in average-risk individuals aged 40- 80 years. Am J Gastroenterol 2006;101:255-62. (Pubitemid 43381664)
22. Centers for Medicare & Medicaid Services. Medicarefpy1 2011 tables for CPT codes; 2011 [cited 2011 Nov 10]. Available from: http://www.cms. gov/apps/physician-fee-schedule/.
23. CVS Pharmacy. Price verification for aspirin and calcium. [cited 2011 Nov 7]. Available from: http://cvs.com.
24. Sonnenberg A, Delco F, Inadomi JM. Cost-effectiveness of colonoscopy in screening for colorectal cancer. Ann Int Med 2002;133: 573-84.
25. King JT, Tsevat J, Lave JR, Roberts MS. Willingness to pay for a quality-adjusted life year: implications for societal health care resource allocation. Med Decis Making 2005;25:667-77. (Pubitemid 41667135)
26. Casado-Arroyo R, Gargallo C, Arbeloa AL. Balancing the risk and benefits of low-dose aspirin in clinical practice. Best Pract Res Clin Gastroenterol 2012;26:173-84.
27. Thiagarajan P, Jankowski JA. Aspirin and NSAIDS: benefits and harms for the gut. Best Pract Res Clin Gastroenterol 2012;26:197-206.
28. Rothwell PM, Wilson M, Elwin C-E, Norrving B, Algra A, Warlow CP, et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomized trials. Lancet 2010;376:1741-50.
29. Rothwell PM, Fowkes FGR, Belch JFF, Warlow CP, Meade TW. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomized trials. Lancet 2011;377:31-41.
30. Bischoff-Ferrari HA, Rees JR, Grau MV, Barry E, Gui J, Baron JA. Effect of calcium supplementation on fracture risk: a double-blind randomized controlled trial. Am J Clin Nutr 2008;87:1945-51. (Pubitemid 351872663)
31. McNeil C.Newdata on aspirin and colorectal cancer brings call for new guidelines, more research. J Natl Cancer Inst 2012;104:172-73, 177.